Dr Alice Berger Receives $200K Grant for Lung Cancer Research
Dr Alice Berger. Credit: Bo Jungmayer / Fred Hutch News Service
Dr. Alice Berger, a translational researcher at Fred Hutchinson Cancer Research Center, has received a $200,000, two-year award — the Lori Monroe Scholarship for Lung Cancer Research — to advance her scientific focus on the genetics of lung cancer in women who have never smoked.
She will use the scholarship, funded by the Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer, to perform genome sequencing on lung tumors found in women with no history of smoking who participated in the Women’s Health Initiative. The WHI, coordinated by Fred Hutch, is one of the largest U.S. prevention studies of its kind, involving more than 161,000 women.
Berger will conduct the research in collaboration with Dr. Garnet Anderson, principal investigator of the WHI Clinical Coordinating Center, senior vice president and director of the Public Health Sciences Division and Fred Hutch 40th Anniversary Endowed Chair.
According to Berger, previous genetic studies of lung cancer have focused mainly on tumors from people with a history of smoking; the largest study of never-smokers to date has included only 33 participants.
“In the small number of tumors from never-smokers who have been profiled, we can see that the genetic changes in never-smokers are very different from that of smokers,” said Berger, a researcher in the Hutch’s Human Biology and Public Health Sciences divisions.
“The goal of this project is to identify new potential drug targets in lung cancer and to better understand the etiology of lung cancer in patients without a smoking history,” she said.
Over the course of the WHI study, more than 3,600 women developed lung cancer, including 583 who had never smoked. By studying genetic alterations in lung-tumor tissue from 110 never-smokers in the WHI cohort, Berger aims to increase the number of such sequenced tumors more than three-fold.
“The WHI provides an uncommon and possibly unique opportunity to study the genetic determinants of lung cancer among never-smokers,” Anderson said. “The size of the resource and the strength of the WHI database, which includes detailed information about smoking history and other exposures, offer an opportunity for the WHI to make a timely and significant contribution to our knowledge of lung cancer in the subset of individuals for whom the cause is often a mystery.”
The rate of lung cancer in never-smokers is on the rise; from 1990 through 2013, the percentage of patients with non-small-cell lung cancer who never smoked spiked from 8 percent to 14.9 percent. In 2016 in the U.S., 24 percent of lung cancer cases in women and 17 percent of lung cancer cases in men were in those who never smoked, which is defined as smoking 100 or fewer cigarettes in one’s lifetime.
Berger’s scholarship is named in honor of registered nurse and patient advocate Lorraine “Lori” Gail Monroe, co-founder of the Lung Cancer Foundation of America, who passed away from the disease in 2013 at age 55.
This article has been republished from materials provided by Fred Hutch. Note: material may have been edited for length and content. For further information, please contact the cited source.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.